Main
>
ONCOLOGY (**)
>
Urothelial Carcinoma
>
TREAT.:
>
USA. B. PD-1 MAb>
USA. B. PD-1 MAb>'s subsections
(*) EU CE Mark Date: 2022. 04.05
(*) USA Approval Date: 2021. 08.20
>high risk of recurrence after>
Company
Generic Name: nivolumab
Patent
RTM
RTM Web-Site
USA. B. PD-1 MAb>'s products
This section has no products
(*) EU CE Mark Date: 2022. 04.05
(*) USA Approval Date: 2021. 08.20
>high risk of recurrence after>
Company
Generic Name: nivolumab
Patent
RTM
RTM Web-Site